Teva Pharma (TEVA) Misses Q3 EPS by 3c; Lowers Revenue Outlook on FX
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500, Nasdaq futures rise on tech boost
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
Teva Reports Third Quarter 2022 Financial Results
November 3, 2022 7:00 AM EDTKey financial highlights and outlook
Revenues of $3.6 billion GAAP diluted EPS of $0.05 Non-GAAP diluted EPS of $0.59 Cash flow generated from operating activities of $543 million Free cash flow of $685 million 2022 revenues outlook revised mainly due to continued foreign exchange headwinds; non-GAAP tax rate outlook range revised to 12% - 14%; operating income, Adjusted EBITDA, EPS and free cash flow reaffirmed: Revenues of $14.8 - $15.4 billion vs. previous range of $15.0 - $15.6 billion Adjusted EBITDA of $4.7 - $5.0 billion Non-GAAP diluted EPS of $2.40 - $2.60 Free... More